Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Mitsubishi Tanabe Incurs 60 Billion-Plus Yen Operating Loss in 1st Half as Parkinson’s Program Lags
To read the full story
Related Article
BUSINESS
- Japan Pharma Market Crosses 11 Trillion Yen in FY2023, Keytruda Triumphs: IQVIA
May 22, 2024
- Biogen Files Tofersen as Japan’s 1st Genetic ALS Drug
May 22, 2024
- Novo to Prioritize Markets for GLP-1 Supply, Touts Massive Lift in Capacity
May 22, 2024
- Japan’s 1st Stelara Biosimilar to Hit Market on May 29
May 22, 2024
- Servier Trains Sight on 50% Oncology Sales Ratio by 2030, Set to Upsize Japan Biz
May 22, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…